Roche, AbbVie Snag Priority Review for Venetoclax

Roche’s Genentech unit has scooped up priority review from the FDA for venetoclax for the treatment of chronic lymphocytic leukemia.

Developed in partnership with AbbVie, venetoclax is a small molecule inhibitor of the BCL-2 protein. It received breakthrough therapy designation in April 2015.